A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'-monophosphate in asthmatic patients.

Inhaled corticosteroids decrease airway responsiveness in asthma partly through suppression of airway inflammation. We have previously demonstrated that inhaled budesonide reduced airway responsiveness to the mast cell stimulus adenosine-5'-monophosphate (AMP) to a threefold greater extent than to methacholine and sodium metabisulfite, suggesting that AMP responsiveness may be a more sensitive marker of airway inflammation and steroid action in order to assess a dose-response relationship. To investigate this, we studied the effects of three doses of the novel corticosteroid ciclesonide (50 micrograms, 200 micrograms, and 800 micrograms) inhaled as a dry powder twice daily on airway responsiveness to AMP and inflammatory parameters in induced sputum. In a three-parallel-dose group, double-blind, placebo-controlled, randomized, crossover study, with a washout period of 3 to 8 wk, a total of 29 patients with mild to moderate allergic asthma underwent AMP challenge and sputum induction before and after 14 d of treatment with ciclesonide or matched placebo. Compared with placebo, ciclesonide 100 micrograms, 400 micrograms, and 1,600 micrograms daily reduced airway responsiveness to AMP by 1.6 (95% confidence interval [CI], -0.1 to 3.4, not significant [NS]), 2.0 (95% CI, 0.4 to 3.6, p < 0.05), and 3.4 (95% CI, 2.3 to 4. 4, p < 0.05) doubling doses, respectively, and this reduction in airway responsiveness was dose-dependent (p = 0.039). A significant reduction in the percentage of eosinophils in induced sputum was observed after 400 micrograms and 1,600 micrograms daily ciclesonide (p < 0. 05), but this was not dose-dependent. Sputum eosinophil cationic protein (ECP) was significantly reduced after 400 micrograms daily ciclesonide only (p < 0.05). Thus, in patients with mild to moderate asthma, assessment of airway responsiveness to AMP, rather than inflammatory parameters in induced sputum, represents a sensitive method to evaluate a dose-response relationship of an inhaled corticosteroid and may have applications in evaluating other novel inhaled corticosteroids.

[1]  P. Barnes,et al.  Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma , 1999, Thorax.

[2]  K. Chung,et al.  An inhaled steroid improves markers of airway inflammation in patients with mild asthma. , 1998, The European respiratory journal.

[3]  S. Holgate,et al.  Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? , 1997, Thorax.

[4]  D. Postma,et al.  Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. , 1997, American journal of respiratory and critical care medicine.

[5]  P. Barnes,et al.  Pathophysiology of asthma. , 2003, British journal of clinical pharmacology.

[6]  B. Schmekel,et al.  Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma: a controlled study. , 1996, Thorax.

[7]  E. Israel,et al.  Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. , 1996, American journal of respiratory and critical care medicine.

[8]  R. de Bruijn,et al.  Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma. , 1996, Thorax.

[9]  M. Calderón,et al.  Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. , 1994, American journal of respiratory and critical care medicine.

[10]  P. Barnes,et al.  Efficacy and Safety of Inhaled Corticosteroids in Asthma , 1993 .

[11]  D. Postma,et al.  Airway responsiveness to adenosine 5'-monophosphate in chronic obstructive pulmonary disease is determined by smoking. , 1993, The American review of respiratory disease.

[12]  P. Barnes,et al.  Greater effect of inhaled budesonide on adenosine 5'-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma. , 1992, The American review of respiratory disease.

[13]  A. Tattersfield,et al.  Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air hyperventilation in patients with asthma. , 1991, Thorax.

[14]  E. Juniper,et al.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. , 1990, The American review of respiratory disease.

[15]  A. Kagey‐Sobotka,et al.  Adenosine potentiates mediator release from human lung mast cells. , 1988, The American review of respiratory disease.

[16]  S. Holgate,et al.  Adenosine-induced bronchoconstriction in asthma. Role of parasympathetic stimulation and adrenergic inhibition. , 1985, The American review of respiratory disease.

[17]  E. Juniper,et al.  Effect of beclomethasone dipropionate on bronchial responsiveness to histamine in controlled nonsteroid-dependent asthma. , 1985, The Journal of allergy and clinical immunology.

[18]  S. Holgate,et al.  Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. , 1984, Biochemical pharmacology.

[19]  R. Dahl,et al.  Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma. , 2015, The American review of respiratory disease.

[20]  R. Dahl,et al.  Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. , 1982, European journal of respiratory diseases. Supplement.

[21]  N. Lefcoe,et al.  A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. , 1977, Journal of Allergy and Clinical Immunology.

[22]  K. Palmer,et al.  Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma. , 1973, Lancet.

[23]  D. Wolfe,et al.  Nonparametric Statistical Methods. , 1974 .